Mikhail Krasavin

Dr. Mikhail Krasavin

Auto-generated profile, based on publicly available information

Dr. Mikhail Krasavin

Institute of Chemistry, Saint Petersburg State University, St Petersburg, Russia

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2019 in Molecules
Verified
Journal Article
Open access
PDF file
CEChupakhin Evgeny
Chupakhin Evgeny
Olga BabichOlga Babich
Olga Babich
Alexander ProsekovAlexander Prosekov
Alexander Prosekov
LALyudmila Asyakina
Lyudmila Asyakina
Mikhail KrasavinMikhail Krasavin
Mikhail Krasavin
Spirocyclic motifs are emerging privileged structures for drug discovery. They are also omnipresent in the natural products domain. However, until today, no attempt to analyze the structural diversity of various spirocyclic motifs occurring in natural products and their relative populations with unique compounds reported in the literature has been undertaken. This review aims to fill that void and analyze the diversity of structurally unique natural products containing spirocyclic moieties of various sizes.

30 September 1999 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
GPGary H. Posner
Gary H. Posner
PPPoonsakdi Ploypradith
Poonsakdi Ploypradith
†P† Michael H. Parker
† Michael H. Parker
HOHardwin O'Dowd
Hardwin O'Dowd
†W† Soon-Hyung Woo
† Soon-Hyung Woo
TSTheresa A. Shapiro
Theresa A. Shapiro

1 February 2006 in Tetrahedron Letters
Verified
Journal Article
Closed access
VPVladislav Z. Parchinsky
Vladislav Z. Parchinsky
OSOlga Shuvalova
Olga Shuvalova
OUOlga Ushakova
Olga Ushakova
DKDmitry V. Kravchenko
Dmitry V. Kravchenko
Mikhail KrasavinMikhail Krasavin
Mikhail Krasavin

Verified
Journal Article
Open access
PDF file
SKSTANISLAV A. KALININ
STANISLAV A. KALININ
AMAnna Malkova
Anna Malkova
TSTatiana Sharonova
Tatiana Sharonova
Vladimir SharoykoVladimir Sharoyko
Vladimir Sharoyko
ABAlexander Bunev
Alexander Bunev
Mikhail KrasavinMikhail Krasavin
Mikhail Krasavin
Combination therapy is becoming imperative for the treatment of many cancers, as it provides a higher chance of avoiding drug resistance and tumor recurrence. Among the resistance-conferring factors, the tumor microenvironment plays a major role, and therefore, represents a viable target for adjuvant therapeutic agents. Thus, hypoxia and extracellular acidosis are known to select for the most aggressive and resilient phenotypes and build poorly responsive regions of the tumor mass. Carbonic anhydrase (CA, EC 4.2.1.1) IX isoform is a surficial zinc metalloenzyme that is proven to play a central role in regulating intra and extracellular pH, as well as modulating invasion and metastasis processes. With its strong association and distribution in various tumor tissues and well-known druggability, this protein holds great promise as a target to pharmacologically interfere with the tumor microenvironment by using drug combination regimens. In the present review, we summarized recent publications revealing the potential of CA IX inhibitors to intensify cancer chemotherapy and overcome drug resistance in preclinical settings.

15 November 2006 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
AIAlexei Ilyin
Alexei Ilyin
VKVolodymyr Kysil
Volodymyr Kysil
Mikhail KrasavinMikhail Krasavin
Mikhail Krasavin
IKIrina Kurashvili
Irina Kurashvili
AIAlexandre V. Ivachtchenko
Alexandre V. Ivachtchenko